Olfactory dysfunction in β-thalassemia major patients treated with iron-chelating agents.

Ear Nose Throat J

Department of Otorhinolaryngology, Muğla Sıtkı Koçman Üniversitesi Tıp Fakültesi Orhaniye Mahallesi Haluk Özsoy Caddesi 48000/Muğla, Turkey.

Published: July 2018

Ocular and ophthalmologic adverse effects may occur in patients with β-thalassemia major (BTM) treated regularly with blood transfusions and iron-chelating agents. We hypothesized that olfactory dysfunction may be present in this patient population. We aimed to investigate olfactory dysfunction in patients with BTM and to determine etiologic factors. A total of 43 patients with BTM were included in the study. Forty-three subjects without nasal complaints, history of facial trauma, or nasal surgery were included as the controls. All participants had nasal endoscopy. The use of iron-chelating agents by patients with BTM and their duration of use were recorded, as well as hemoglobin and ferritin levels. The Sniffin' Sticks test (SST) was used to assess olfactory function, comparing results between the BTM and control groups. The correlations of SST scores with the other study parameters were analyzed. Eight (18.6%) of 43 patients in the BTM group and none of the subjects in the control group had hyposmia (p < 0.001). Older age, low hemoglobin level, and longer use of deferoxamine were found to be correlated with olfactory dysfunction. Olfactory dysfunction can occur in patients with BTM treated with iron-chelating agents. The results suggest that screening for olfactory function should be part of the routine follow-up of patients with BTM.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0145561317096010-1103DOI Listing

Publication Analysis

Top Keywords

patients btm
24
olfactory dysfunction
20
iron-chelating agents
16
β-thalassemia major
8
patients
8
treated iron-chelating
8
occur patients
8
btm
8
btm treated
8
olfactory function
8

Similar Publications

Objectives: To determine the prevalence of family planning practice among the parents of children affected with beta thalassemia major (BTM) and to determine the relationship between various factors and family planning practice in Makran division Balochistan.

Methods: A cross-sectional observational study was conducted on 190 parents having BTM children registered in thalassemia care centers throughout the Makran division from May 2023 to October 2023. The structured questionnaire was used and data was collected using the non-probability convenience technique.

View Article and Find Full Text PDF

Teriparatide (TPT) acts against severe primary (postmenopausal) osteoporosis (MOP), and it requires continuation with another anti-resorptive drug to conserve or enhance the effects on fracture risk reduction. To analyse the sequential pharmacotherapy in MOP who were treated upon a 24-month daily 20 µg TPT protocol (24-mo-TPT) followed by another 12 months of anti-resorptive drugs (12-mo-AR) amid real-life settings. 1.

View Article and Find Full Text PDF

Trends in osteoporosis assessment, diagnosis after fragility fractures, and treatment for hospitalized patients with osteoporosis or fragility fractures between 2012 and 2021.

Arch Osteoporos

January 2025

Department of Endocrinology and Diabetes, Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, Xiamen Diabetes Institute, The First Affiliated Hospital of Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China.

Unlabelled: Our study investigated trends in osteoporosis management in Xiamen from 2012 to 2021, revealing improvements in screening and treatment, although medication use remained low. Additionally, we identified factors that may influence medication use and emphasized the importance of effective osteoporosis management strategies.

Purpose: The goal of the current study is to explore trends in assessment, diagnosis after fragility fractures, and osteoporosis treatment among hospitalized patients in Xiamen, China, between 2012 and 2021.

View Article and Find Full Text PDF

Long-Term Histological Evaluation of a Novel Dermal Template in the Treatment of Pediatric Burns.

Bioengineering (Basel)

December 2024

Paediatric Burn Center, Children's Skin Center, Department of Surgery, University Children's Hospital Zurich, Lenggstrasse 30, 8008 Zurich, Switzerland.

For pediatric patients with full-thickness burns, achieving adequate dermal regeneration is essential to prevent inelastic scars that may hinder growth. Traditional autologous split-thickness skin grafts alone often fail to restore the dermal layer adequately. This study evaluates the long-term effect of using a NovoSorb Biodegradable Temporizing Matrix (BTM) as a dermal scaffold in four pediatric patients, promoting dermal formation before autografting.

View Article and Find Full Text PDF

Reproductive Health in Women with Major β-Thalassemia: Evaluating Ovarian Reserve and Endocrine Complications.

Metabolites

December 2024

IVF Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.

Article Synopsis
  • Thalassemia is a genetic blood disorder causing anemia due to impaired production of hemoglobin chains, leading to the breakdown of red blood cells.
  • Regular blood transfusions, the standard treatment, can result in iron overload that adversely affects major organs, particularly in women, increasing risks of hormonal issues and reproductive challenges.
  • The review discusses the disease's impact on female reproductive health and the potential of metabolomics to guide better treatment approaches for managing thalassemia-related complications.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!